Related references
Note: Only part of the references are listed.Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
John P. Leonard et al.
BLOOD (2012)
Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Keith T. Flaherty et al.
CLINICAL CANCER RESEARCH (2012)
Modeling a Lethal Prostate Cancer Variant with Small-Cell Carcinoma Features
Vassiliki Tzelepi et al.
CLINICAL CANCER RESEARCH (2012)
[18F] FLT-PET Imaging Does Not Always Light Up Proliferating Tumor Cells
Cathy C. Zhang et al.
CLINICAL CANCER RESEARCH (2012)
Evidence for Efficacy of New Hsp90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate Tumors
Margaret M. Centenera et al.
CLINICAL CANCER RESEARCH (2012)
mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer
Matthew J. Schiewer et al.
ENDOCRINE-RELATED CANCER (2012)
Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy
Patrick J. Roberts et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
The AR dependent cell cycle: Mechanisms and cancer relevance
Matthew J. Schiewer et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2012)
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
G. K. Schwartz et al.
BRITISH JOURNAL OF CANCER (2011)
Deregulation of FGFR1 and CDK6 oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the MIR9 family
Paula Rodriguez-Otero et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells
Lars Anders et al.
CANCER CELL (2011)
Early G1 Cyclin-Dependent Kinases as Prognostic Markers and Potential Therapeutic Targets in Esophageal Adenocarcinoma
Amin Ismail et al.
CLINICAL CANCER RESEARCH (2011)
Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
Gottfried E. Konecny et al.
CLINICAL CANCER RESEARCH (2011)
Pharmacotherapeutic Management of Locally Advanced Prostate Cancer Current Status
Jarad M. Martin et al.
DRUGS (2011)
Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
Chellappagounder Thangavel et al.
ENDOCRINE-RELATED CANCER (2011)
New Hormonal Therapies for Castration-Resistant Prostate Cancer
Elahe A. Mostaghel et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2011)
Cyclin D1 Is a Selective Modifier of Androgen-dependent Signaling and Androgen Receptor Function
Clay E. S. Comstock et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Whether to Target Single or Multiple CDKs for Therapy? That is the Question
Jozefa Wesierska-Gadek et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2011)
Common Gene Rearrangements in Prostate Cancer
Mark A. Rubin et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A Robust High-Content Imaging Approach for Probing the Mechanism of Action and Phenotypic Outcomes of Cell-Cycle Modulators
Jeffrey J. Sutherland et al.
MOLECULAR CANCER THERAPEUTICS (2011)
A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers
Siwanon Jirawatnotai et al.
NATURE (2011)
Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer
Ana Aparicio et al.
NATURE REVIEWS UROLOGY (2011)
A bioinformatical and functional approach to identify novel strategies for chemoprevention of colorectal cancer
D. M. Heijink et al.
ONCOGENE (2011)
ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
Todd W. Miller et al.
CANCER DISCOVERY (2011)
Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer
Karen E. Knudsen et al.
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM (2011)
A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
Marta Puyol et al.
CANCER CELL (2010)
Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts
Karine Michaud et al.
CANCER RESEARCH (2010)
Cyclin D2-Cyclin-Dependent Kinase 4/6 Is Required for Efficient Proliferation and Tumorigenesis following Apc Loss
Alicia M. Cole et al.
CANCER RESEARCH (2010)
Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors
Neil Johnson et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2010)
Proliferative Suppression by CDK4/6 Inhibition: Complex Function of the Retinoblastoma Pathway in Liver Tissue and Hepatoma Cells
Dayana B. Rivadeneira et al.
GASTROENTEROLOGY (2010)
The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression
Ankur Sharma et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
J. L. Dean et al.
ONCOGENE (2010)
Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
W. Ruprecht Wiedemeyer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The E2F1/Rb and p53/MDM2 Pathways in DNA Repair and Apoptosis: Understanding the Crosstalk to Develop Novel Strategies for Prostate Cancer Radiotherapy
Thirupandiyur Udayakumar et al.
SEMINARS IN RADIATION ONCOLOGY (2010)
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Qianben Wang et al.
CELL (2009)
Advancing Bioluminescence Imaging Technology for the Evaluation of Anticancer Agents in the MDA-MB-435-HAL-Luc Mammary Fat Pad and Subrenal Capsule Tumor Models
Cathy Zhang et al.
CLINICAL CANCER RESEARCH (2009)
Cyclin-dependent kinase inhibitors as potential targeted anticancer agents
Ivan Diaz-Padilla et al.
INVESTIGATIONAL NEW DRUGS (2009)
Treatment of Growing Teratoma Syndrome.
David J. Vaughn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Crystal structure of human CDK4 in complex with a D-type cyclin
Philip J. Day et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH (2009)
A novel therapeutic combination using PD 0332991 and bortezomib: Study in the 5T33MM myeloma model
Eline Menu et al.
CANCER RESEARCH (2008)
Tailoring to RB: tumour suppressor status and therapeutic response
Erik S. Knudsen et al.
NATURE REVIEWS CANCER (2008)
Cellular mechanisms of tumour suppression by the retinoblastoma gene
Deborah L. Burkhart et al.
NATURE REVIEWS CANCER (2008)
Cyclin degradation for cancer therapy and chemoprevention
Sarah J. Freemantle et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2007)
Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia
Lisheng Wang et al.
BLOOD (2007)
Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer
Yelena B. Wetherill et al.
MOLECULAR CANCER THERAPEUTICS (2006)
A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6
Linda B. Baughn et al.
CANCER RESEARCH (2006)
Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition
Heshu Lu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity
Michal Marzec et al.
BLOOD (2006)
Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors
I Collins et al.
CURRENT OPINION IN PHARMACOLOGY (2005)
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
PL Toogood et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells
JTE Lim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer
G Liu et al.
CLINICAL CANCER RESEARCH (2004)
The crystal structure of human CDK7 and its protein recognition properties
G Lolli et al.
STRUCTURE (2004)
Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol
JP Thomas et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
Share Paper
